Assessment of response to treatment with the PI3K/mTOR inhibitor BEZ235 with FLT PET in a tumor xenograft model

被引：0
|
作者：
Wanek, T. [1 ]
Fuereder, T. [2 ]
Pflegerl, P. [2 ]
Jaeger-Lansky, A. [2 ]
Hoeflmayer, D. [2 ]
Strommer, S. [2 ]
Mueller, M. [2 ]
Langer, O. [1 ]
Kuntner, C. [1 ]
Wacheck, V. [2 ]
机构：
[1] Austrian Inst Technol, Seibersdorf, Austria
[2] Med Univ Vienna, Vienna, Austria
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2010年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S298 / S299
页数：2
相关论文
共 50 条
  • [31] Preclinical efficacy of a dual PI3K-mTOR inhibitor, BEZ235 in triple negative breast cancer
    Dey, N.
    Wu, H.
    Sun, Y.
    De, P.
    Leyland-Jones, B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S17 - S17
  • [32] BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway
    Liu, Xueke
    Xie, Chunmei
    Li, Amin
    Zhang, Yinci
    Liu, Xinkuang
    Zhou, Shuping
    Shen, Jing
    Huo, Zhen
    Gao, Weiya
    Ma, Yongfang
    Xu, Ruyue
    Xing, Yingru
    Xie, Yinghai
    Cai, Shuyu
    Tang, Xiaolong
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2019, 11 (12): : 7255 - 7271
  • [33] Effects of the Specific PI3K Inhibitor BKM120, the Dual PI3K/mTOR Inhibitor BEZ235, and Specific mTOR Inhibitors Everolimus and Temsirolimus in Renal and Hepatic Carcinoma Models Resistant to Sunitinib and Sorafenib
    Serova, M.
    Raballand, A.
    Dos Santos, C.
    Riveiro, E.
    Raymond, E.
    Faivre, S.
    de Gramont, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 113 - 113
  • [34] Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake
    Fuereder, Thorsten
    Wanek, Thomas
    Pflegerl, Pamina
    Jaeger-Lansky, Agnes
    Hoeflmayer, Doris
    Strommer, Sabine
    Kuntner, Claudia
    Wrba, Friedrich
    Werzowa, Johannes
    Hejna, Michael
    Mueller, Markus
    Langer, Oliver
    Wacheck, Volker
    CLINICAL CANCER RESEARCH, 2011, 17 (16) : 5322 - 5332
  • [35] SYNTHESIS AND PROCESS OPTIMIZATION OF PI3K/MTOR DUAL INHIBITOR NVP-BEZ235
    Xu, T. S.
    Lei, F.
    Tao, H.
    Li, J. Q.
    Zhang, Z. W.
    Wang, L. X.
    Xu, S.
    Zheng, P. W.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 119 : 31 - 31
  • [36] Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy
    Lin, Shu-Fu
    Huang, Yu-Yao
    Lin, Jen-Der
    Chou, Ting-Chao
    Hsueh, Chuen
    Wong, Richard J.
    PLOS ONE, 2012, 7 (10):
  • [37] Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
    Qu, Yiqing
    Wu, Xiuxiu
    Yin, Yunhong
    Yang, Yan
    Ma, Dedong
    Li, Hao
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2014, 33
  • [38] A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer
    Wei, Xiao X.
    Hsieh, Andrew C.
    Kim, Won
    Friedlander, Terence
    Lin, Amy M.
    Louttit, Mirela
    Ryan, Charles J.
    ONCOLOGIST, 2017, 22 (05): : 503 - +
  • [39] Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
    Yiqing Qu
    Xiuxiu Wu
    Yunhong Yin
    Yan Yang
    Dedong Ma
    Hao Li
    Journal of Experimental & Clinical Cancer Research, 33
  • [40] Effect of NVP-BEZ235, a dual PI3K/mTOR inhibitor, on chemotherapy and antiangiogenic response in pancreatic cancer
    Ostapoff, Katherine T.
    Awasthi, Niranjan
    Yen, Peter L.
    Zhang, Changhua
    Schwarz, Margaret A.
    Brekken, Rolf A.
    Schwarz, Roderich
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345